Effect of FN1 mutation on outcomes of fibronectin glomerulopathy in a systematic review and meta-analysis

Authors

DOI:

https://doi.org/10.22141/2307-1257.11.1.2022.353

Keywords:

fibronectin, fibronectin glomerulopathy, kidney failure, lobular appearance

Abstract

Background. Fibronectin glomerulopathy is an inherited kidney disease that is characterized with extensive depositions of fibronectin in mesangium and subendothelial space. The aim of study is to assess effect of fibronectin gene on decreased renal function and likeliness of recurrence of the disease after kidney transplantation. Materials and methods. In retrospective descriptive studies, fifty-seven patients with fibronectin glomerulopathy were enrolled in this research. Relative risk and Odds ratio for asses­sing effect measures of risk factor on outcomes of disease were used. Results. Of fifty-seven patients with fibronectin glomerulopathy, thirty-six patients (36/57, 63.1 %) were male and twenty-one patients were female (21/57, 36.8 %). Relative risk and Odds ratio of end-stage kidney disease (ESKD) in nephrotic-range proteinuria versus non-nephrotic range proteinuria were assessed 1.33 and 1.39, respectively. Relative risk and Odds ratio of end-stage kidney disease with kidney replacement therapy (KRT) in patients with positive FN1 gene (as risk or contributing factor) versus patients with negative FN1 gene was assessed 0.66 and 0.50, respectively. Risk of recurrence after kidney transplant with nephrotic-range proteinuria was assessed 0.83 (95% confidence interval of 0.1213 to 5.7244) and odds ratio of recurrence after kidney transplant with nephrotic proteinuria versus non-nephrotic range proteinuria was assessed 0.75 (95% confidence interval of 0.03757 to 14.9733) in the current research. Conclusions. Relative risk and odds ratio of end-stage kidney disease in nephrotic-range proteinuria versus non-nephrotic range proteinuria were assessed 1.33 and 1.39, respectively. Therefore, it appears risk of fibronectin gene 1 on end-stage kidney disease with kidney replacement therapy be low.

Downloads

Download data is not yet available.

References

Bürgin M, Hofmann E, Reutter FW, et al. Familial glomerulopathy with giant fibrillar deposits. Virchows Arch A Pathol Anat Histol. 1980;388(3):313-26. doi: 10.1007/BF00430861.

Herrera GA, Turbat-Herrera EA. Renal diseases with organized deposits: an algorithmic approach to classification and clinicopathologic diagnosis. Arch Pathol Lab Med. 2010 Apr;134(4):512-31. doi: 10.5858/134.4.512.

Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. Am J Kidney Dis. 2019 Jul;74(1):120-131. doi: 10.1053/j.ajkd.2018.12.044.

Raparia K, Usman I, Kanwar YS. Renal morphologic lesions reminiscent of diabetic nephropathy. Arch Pathol Lab Med. 2013 Mar;137(3):351-9. doi: 10.5858/arpa.2012-0243-RA.

Thomas PP. Fibrillary, immunotactoid and fibronectin glomerulopathies. In: Nur Elhuda̕s Text Book of glomerular diseases. University of Khartoum; 2012. pp. 581-589.

Zhang T, Zhang W, Zuo K, Cheng Z. Clinicopathologic Features and Outcomes in Fibronectin Glomerulopathy: A Case Series of 19 Patients. Front Med (Lausanne). 2020 Aug 14;7:439. doi: 10.3389/fmed.2020.00439.

Modi SS, Balasubramaniam S, Sunilkumar K. Collagenofibrotic glomerulopathy: A case of glomerular deposition disease in the Indian subcontinent and review of the literature. Saudi J Kidney Dis Transpl. 2020 May-Jun;31(3):681-686. doi: 10.4103/1319-2442.289454.

Nasr SH, Vrana JA, Dasari S, et al. DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney Int Rep. 2017 Aug 8;3(1):56-64. doi: 10.1016/j.ekir.2017.07.017.

Downloads

Published

2022-05-24

How to Cite

Shamekhi, F. (2022). Effect of FN1 mutation on outcomes of fibronectin glomerulopathy in a systematic review and meta-analysis. KIDNEYS, 11(1), 2–9. https://doi.org/10.22141/2307-1257.11.1.2022.353

Issue

Section

Original Articles